Articles Vol. 63 No. 5 (2022) 29/09/2022

COMPARISON OF THE EFFICIENCY AND SAFETY OF ALBENDAZOLE AND PRAZIQUANTEL IN THE TREATMENT OF CYSTICERCOSIS

Dang Thi Thanh1,2, Que Anh Tram3,4, Nguyen Quang Thieu1,2
1 National Institute of Malariology, Parasitology and Entomology
2 Viện Sốt rét - Ký sinh trùng - Côn trùng Trung ương
3 Nghe An Friendship General Hospital
4 Bệnh viện Hữu nghị Đa khoa Nghệ An
Corresponding author: Thanhnimpe.dang7@gmail.com
DOI: 10.52163/yhc.v63i5.427
27 Views
0 Downloads
Keywords
Cysticercosis, praziquantel, albendazole, efficacy, safety.
Abstract

Two drugs recommended to treat cysticercosis (ATSL) are albendazole and praziquantel, however,
there have been few studies comparing these two drugs in Vietnam. Objective: To compare the
efficacy and safety of albendazole and praziquantel in the treatment of ATSL. Methods: 120 patients
with ATSL having similar clinical characteristics were grouped for treatment by albendazole or
praziquantel according to the guidelines of the Ministry of Health. The evaluation was done 6 months
after the treatment. Results: The clinically cure and improvement rates were 61.7% and 38.3%. On
MRI, the rates of complete, partial cure and inefficacy were 65%, 30.8% and 4.2% respectively.
The treatment achieved a cure rate of 51.7%, an improvement rate of 44.2% and an inefficacy rate
of 4.2%. Praziquantel was more efficacious than albendazole in clinical, MR imaging and outcome.
The studied patients did not show any abnormalities in levels of urea or creatinine. The patients
receiving praziquantel had an increase in GPT abnormalities only after the third course. The patients
taking albendazole had an increase in liver enzymes after all treatment courses. The rate of liver
enzyme elevation was higher in the albendazole group than in the praziquantel group. Conclusion:
Praziquantel is more effective and safer than albendazole in the treatment of ATSL.

References
[1]
Ministry of Healt, Decision No.1450/2004/QĐ- Google Scholar
[2]
BYT on issuing the Guideline on diagnosing Google Scholar
[3]
and treating Clonorchiasis, Paragonimus, Teania Google Scholar
[4]
solium and Cysticercosis, 2004. Google Scholar
[5]
Trieu HS, Study of genes, clinical and subclinical pathogens, treating results for Teania spp Google Scholar
[6]
and Teania solium among patients in National Google Scholar
[7]
Institute of Malariology, Parasitology and Google Scholar
[8]
Entomology from 2007 -2010, Medical doctor’s Google Scholar
[9]
thesis, 2013. Google Scholar
[10]
Hong ST, Albendazole and Praziquantel: Review Google Scholar
[11]
and Safety Monitoring in Korea. Infection & Google Scholar
[12]
chemotherapy, 2018, 50(1), 1–10 Google Scholar
[13]
Huang X, Wang Z, Kou J et al., A Large Cohort Google Scholar
[14]
of Neurocysticercosis in Shandong Province, Google Scholar
[15]
Eastern China, 1997-2015. Vector borne and Google Scholar
[16]
zoonotic diseases (Larchmont, N.Y.), 2019, Google Scholar
[17]
(12), 901–907. Google Scholar
[18]
Rolfs A, Mühlschlegel F, Jansen-Rosseck R et Google Scholar
[19]
al., Clinical and immunologic follow-up study of Google Scholar
[20]
patients with neurocysticercosis after treatment Google Scholar
[21]
with praziquantel. Neurology, 1995, 45(3 Pt Google Scholar
[22]
:532-538. Google Scholar
[23]
Pandey S, Malhotra HS, Garg RK et al., Google Scholar
[24]
Quantitative assessment of lesion load and Google Scholar
[25]
efficacy of 3cycles of albendazole in disseminated Google Scholar
[26]
cysticercosis: a prospective evaluation. BMC Google Scholar
[27]
Infectious Diseases, 2020, 20, 220 Google Scholar
[28]
Piloiu C; Dumitrascu DL, Albendazole-Induced Google Scholar
[29]
Liver Injury, American Journal of Therapeutics, Google Scholar
[30]
, 28(3), p e335-e340 Google Scholar
[31]
Sotelo J, Escobedo F, Penagos P, Albendazole vs Google Scholar
[32]
Praziquantel for Therapy for Neurocysticercosis: Google Scholar
[33]
A Controlled Trial. Arch Neurol, 1988, Google Scholar
[34]
(5):532–534. Google Scholar
[35]
Sotelo J, del Brutto OH, Penagos P et al., Google Scholar
[36]
Comparison of therapeutic regimen of Google Scholar
[37]
anticysticercal drugs for parenchymal brain Google Scholar
[38]
cysticercosis. J Neurol 237, 1990, 69–72. Google Scholar
[39]
Son HJ, Kim MJ, Jung KH et al., Google Scholar
[40]
Neurocysticercosis: Clinical Characteristics and Google Scholar
[41]
Changes from 26 Years of Experience in an Google Scholar
[42]
University Hospital in Korea. Korean J Parasitol, Google Scholar
[43]
, 57(3):265-271. Google Scholar